Administered once a week, it aids in significant weight reduction, positioning it as a potential game-changer in obesity management
Adverse events were mainly gastrointestinal, and these were more common with orforglipron than with semaglutide ( Table 1 )
A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding
Four separate peptides in one vial means four separate opportunities for impurity, mislabeling, endotoxin, or degradation risks that are entirely about sourcing and manufacturing and have nothing to do with the molecules intrinsic biology
Codon optimization was necessary for efficient germline BirA expression
Candidates for GLP1 weight loss medications typically have a body mass index (BMI) in the overweight or obese range and may have weightrelated health concerns such as prediabetes, type 2 diabetes, high blood pressure, or elevated cholesterol